New insights into atherosclerotic plaque rupture
Open Access
- 1 February 2001
- journal article
- review article
- Published by Oxford University Press (OUP)
- Vol. 77 (904), 94-98
- https://doi.org/10.1136/pmj.77.904.94
Abstract
Coronary artery atherosclerosis is the major cause of mortality and morbidity in the indus- trialised world. Progressive narrowing of cor- onary arteries causes angina. However, it is rupture of the plaque that causes the cata- strophic consequences of atherosclerosis, such as myocardial infarction. Recent work has identified that the stability of the plaque rather than its absolute size determines the likelihood of rupture, making a change in plaque compo- sition rather than plaque regression a worth- while clinical goal. This review summarises recent advances in the understanding of plaque rupture, and identifies areas in which new therapies may be directed. The vulnerable plaque Myocardial infarction and unstable angina are caused by rupture or erosion of an atheroscle- rotic plaque, with subsequent thrombus for- mation and occlusion of the artery. The plaque that causes a patient's heart attack is not nec- essarily the one that is identified at angio- graphy. Cardiologists conventionally describe coronary artery stenoses as significant when they occupy >50% of the arterial lumen, that is when they become flow limiting. However, a series of postmortem and angiographic studies has identified that nearly 70% of myocardial infarctions are caused by rupture of plaques that cause 70% stenotic (reviewed by Falk et al 1Keywords
This publication has 64 references indexed in Scilit:
- Inhibition of proinflammatory cytokine production by pravastatinThe Lancet, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Upregulation of IGF-I and collagen I mRNA in human atherosclerotic tissue is not accompanied by changes in type 1 IGF receptor or collagen III mRNACoronary Artery Disease, 1996
- Reduction of Serum Cholesterol Levels Alters Lesional Composition of Atherosclerotic PlaquesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Influence of HMG-COA reductase inhibitors on plaque-forming cell (PFC) response in mice.The Journal of Toxicological Sciences, 1995
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.Journal of Clinical Investigation, 1994
- Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.Heart, 1993
- Attenuation of the media of coronary arteries in advanced atherosclerosisThe American Journal of Cardiology, 1986
- Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agentsAtherosclerosis, 1986